Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China - Takeaways - MDSpire

Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China

  • By

  • Wanyan Xiang

  • Jiarong Lu

  • Siqi Zhang

  • Wenjun Zheng

  • Qiuju Li

  • July 6, 2026

  • 0 min

Share

  • 1

    This study evaluated upadacitinib's efficacy and safety for managing immune drift in patients with psoriasis and atopic dermatitis.

  • 2

    Eleven patients participated, with a mean age of 37.4 years, showing significant improvements in IGA, EASI, and PASI scores after four weeks.

  • 3

    IGA 0/1 response rates reached 62.5%, with EASI scores decreasing from 18.0 to 2.5 and PASI scores from 9.4 to 2.8.

  • 4

    Quality of life improved, evidenced by a reduction in DLQI scores from 21.8 to 9.3, with 54.55% of patients showing significant NRS improvement.

  • 5

    No severe adverse events were reported, and only one patient experienced folliculitis, indicating a favorable safety profile for upadacitinib.

Original Source(s)

Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China

  • by Wanyan Xiang, Jiarong Lu, Siqi Zhang, Wenjun Zheng, Qiuju Li

  • July 6, 2026

Related Content

Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma – GASD syndrome by TNF antagonists

Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.